Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
/
RSS Feed
Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071209_anton_hagenbeek.mp3]
You may also like...
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone 1 Feb, 2008 - ASCO Audio Journal of Oncology – June 4th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of Julie Gralow 3 Jun, 2006
- ASCO Audio Journal of Oncology – May 1st, 2006 – In the company of Gordon McVie 1 May, 2006
Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome 27 Mar, 2015
